Viralgen Vector Core

San Sebastian, 
  • Booth: 648

Welcome to ASGCT and Viralgen Vector Core.

Viralgen is gene therapy CDMO, specializing in AAV therapeutics production, created to help broaden the access to life-saving therapeutics and contribute to the advancement of health and human welfare around the world.  Through our proprietary Pro10™ suspension manufacturing platform, we deliver industry-leading titers and quality for all AAV serotypes to our client partners, optimizing speed to market and cost-of-goods to accelerate clinical development and commercialization.


  • 2000L Bioreactor in Viralgen’s Pro10™ Process
    Viralgen is a specialist AAV only CDMO focused on scalable, platform driven production. We received the cGMP certification in 2019 and since then we have produced over 500 batches at the preclinical, toxicology and cGMP scales in our facility in Spain....

  • Viralgen specializes in the production of AAV gene therapy vectors using our proprietary suspension, triple transfection Pro10™ platform. Pro10™ is a unique high yield universal system that can produce all serotypes and chimeric forms of rAAV. The Pro10TM process utilizes a scalable upstream and robust purification process.  

    Scale and cGMP Offerings:


    2L scale: feasibility study and manufacturability assessment.

    50L scale: non-GMP material to supply Toxicology/biodistribution studies, used as reference material or to start your stability studies.

    250L/500L scales:  Viralgen maintains 4 independent state-of-the-art cGMP suites, providing the capability to continuously manufacture 4 different products simultaneously. Viralgen uses 250L and 500L single-use stirred-tank bioreactors in manufacturing.


    2000L scale: Viralgen offers up to 2000L in each of our 9 suites for late phase and commercial manufacturing.